Project Details
Description
A Post-Authorization Safety Study (PASS) to Assess Long-term Safety in Patients with Pompe Disease Treated with Avalglucosidase alfa in the Real-World Setting: the SAVANT (Safety assessment of AValglucosidase Alfa as a Novel Treatment) study
Status | Active |
---|---|
Effective start/end date | 7/24/24 → 9/9/35 |
Funding
- SANOFI-AVENTIS US